JUNO is developing immunotherapies for lymphomas, leukemias and other cancers. It is an upcoming IPO
This is a call to buy in the IPO at the IPO price. To be clear, this is not a call to buy the stock post IPO or in the open market when the stock starts trading.
Consider contacting your broker and requesting up to 150% of the full core position size. Consider buying only if the IPO is priced under $21, preferably under $20.
Hard stops are mandatory in the zone of $0.01 below the offering price to $0.13 below the offering price.